In a phase I clinical trial the effect of the highly sulfated polyanion "Aprosulate" was studied in healthy volunteers using different coagulation and platelet function parameters. Eighteen healthy volunteers aged 21 to 30 years received two single subcutaneous doses of aprosulate (0.5 mg/kg body weight; 1.0 mg/kg body weight), or unfractionated heparin (Calciparin&reg; 7,500 IU). The washout period between the different drugs/doses was at least 7 days. Coagulation and platelet function parameters (activated partial thromboplastin time, Heptest, fibrinogen, von Willebrand factor, ristocetin cofactor, platelet adhesion to siliconized glass, and platelet-induced thrombin generation time [a new method for measuring thrombin generation in platelet-rich plasma in the presence of platelets]) were assessed during 24 hours after each injection. Aprosulate led to a significant and dose-dependent prolongation of activated partial thromboplastin time and Heptest. This effect lasted for 4 hours (activated partial thromboplastin time) to 8 hours (Heptest). Activated partial thromboplastin time was not prolonged after the injection of unfractionated heparin (7,500 IU). Fibrinogen, von Willebrand factor, and ristocetin cofactor remained unchanged with both drugs. Platelet induced thrombin generation time was slightly prolonged and platelet adhesion was slightly diminished up to 2 hours using 0.5 mg/kg aprosulate, and up to 4 hours using 1.0 mg/kg aprosulate while the platelet induced thrombin generation time system was not influenced by the subcutaneous injection (7,500 IU) of unfractionated heparin. Both drugs and doses were well tolerated. Plasma transaminase concentrations alanin aminotransferase and aspartate aminotransferase serum values were slightly increased in some volunteers but returned to normal during or after the study (<4 weeks). Further clinical trials will have to establish whether aprosulate is an effective drug for the prophylaxis of deep venous thrombosis.
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Bislactobionic acid amides as aprosulate, a new class of fully synthesized highly sulfated synthetic glycosaminoglycans were developed with the aim to obtain antithrombotic drugs with a low risk of bleeding in comparison with unfractionated heparin (UFH) or low molecular weight heparins (LMWHs) (1) (2) (3) (4) . Aprosulate (Luitpold Pharma Munich, Germany) has a molecular weight of 2,388 d. In vitro and ex vivo it prolongs activated partial thromboplastin time (aPTT), thrombin time, and Heptest (Haemachen Int., St. Louis, MO, USA) in different animal and human plasmas (5) (6) (7) (8) . In contrast to UFH and LMWH it has very little anti-IIaand no anti-Xa-effect. Its anticoagulant effect is not mediated by an-tithrombin III (AT III). Aprosulate inhibits the formation of factor Villa and factor IXa (9) (10) (11) .
According to Kijowski et al. (12) aprosulate exerts its anticoagulant effect in plasma as a result of its interaction with heparin-cofactor II. The same authors also described that protamine sulfate partially neutralizes the anticoagulant activity of aprosulate in human and monkey plasma. Aprosulate, as some LMWHs and other sulfated glycosaminoglycans, stimulates the synthesis of heparansulfate by cultured endothelial cells (13) . Inhibition of thrombin generation probably is the decisive mode of action of aprosulate as an anticoagulant.
Aproxulate has shown dose-dependent antithrombotic effects in different arterial and venous animal models of thrombosis at doses ranging from 1 to 30 mg/kg (5, 8, (14) (15) (16) (17) (18) . Injection of protamine sulfate partially reversed the antithrombotic effects of aprosulate (16) .
In an earlier study, healthy volunteers were given aprosulate in subcutaneous doses between 0.25 and 2 mg/kg prolonged aPTT and Heptest dose dependently for up to 10 hours (19) .
It seemed of interest to study whether aprosulate inhibits platelet adhesion or thrombin generation in the presence of platelets in parallel to its effect on aPTT and Heptest. Different coagulation assays and these parameters were studied in a phase I clinical trial in healthy volunteers in comparison with UFH.
MATERIAL AND METHODS

Study subjects
The study included 18 healthy male volunteers aged 21 to 30 years who had given written consent. The study was approved by the ethical committee of the J.W. Goethe-University Frankfurt a.M., Germany and was sponsored by Luitpold Pharma.
Design of the study
In a single blind, randomized, prospective, threeperiod crossover phase I trial the effect of aprosulate (one ampoule containing 150 mg aprosulate in I mL aqueous solution) in comparison with UFH on different coagulation parameters and on platelet adhesion was studied.
Two different single doses of aprosulate (0.5 mg/kg bodyweight; 1.0 mg/kg bodyweight) as well as Calcipa-rin&copy;/Sanofi-0.3 mL injection solution corresponding to 7,500 IU UFH were applied subcutaneously. There were two washout periods of I week each between the different doses.
Inclusion criteria
Healthy male volunteers, aged 18-36 years with normal coagulation values, and a normal ECG were included in the study.
Aprosulate
Bislactobionic acid amides are synthesized from alkylene diamine and lactobionic acid lactone starting material. In contrast to heparin and heparinoids, bislactobionic acid amides are not polydisperse, and are purified by differential precipitation and chromatographic procedures. Identity and purity were established by different analytic methods including elemental analysis, refractive index, 13C nuclear magnetic resonance (13C-NMR), Platelet adhesion to siliconized glass (28) Citrated PRP was used for this procedure. A siliconized Bfrcker counting chamber was filled with 10 pLL PRP. Ten minutes later the coverslip was removed and the counting chamber was then gently rinsed 10 times in a citrate saline mixture (NaCI 0.9%: Na-citrate; v:v = 10.1 ). For fixation, the chamber was put into a 6% buffered glutaraldehyde solution for 5 minutes. The number of platelets attached on an area of 1/20 mm was then counted under a microscope using Nomarski-optics. The number of platelets obtained divided by the number of platelets in citrated PRP resulted in the adhesion index (normal range 0.8-1.7). Platelet adhesion to siliconized glass and PITT were measured 30 minutes after blood sampling. ,<.
Safety parameters
Laboratory assessments including hematologic parameters were performed before and 24 hours after drug application. Spontaneous observations on tolerance were recorded following the single injections. Injection sites were inspected 12 and 24 hours after the subcutaneous administrations.
Statistics
Mean values and standard deviations were calculated for comparisons. In addition Wilcoxon's signed rank test was used.
RESULTS
In a 3-period crossover study the anticoagulant activities and the effects on platelet adhesion of two different doses (0.5 mg/kg; 1.0 mg/kg) of aprosulate were compared with 7,500 IU of Calciparing in 18 healthy male volunteers. Single subcutaneous doses were applied with a washout period of 7 days between each drug/dose. Activated partial thromboplastin time (Fig. 1 A) and
Heptest (Fig. 1B ) were significantly (p < .05) and dose dependently prolonged for 8 hours (Heptest) and for 2 to 4 hours (aPTT), respectively, after each subcutaneous dose of aprosulate. The subcutaneous administration of 7,500 IU Calciparin4' also led to a significant prolongation of Heptest up to 4 hours whereas aPTT increase did not reach significance. In contrast to UFH (7,500 IU) and to the lower dose of aprosulate (0.5 mg/kg), aprosulate 1.0 mg/kg significantly prolonged aPTT (2 to 4 hours after the injection). Platelet-induced thrombin generation time was moderately and dose dependently, but not significantly, prolonged for 2 hours using 0.5 mg/kg aprosulate and 4 hours using 1.0 mg/kg aprosulate after the subcutaneous application. However, PITT did not change after subcutaneous administration of 7,500 IU Calciparing (Fig.   1 C) . Platelet adhesion was slightly inhibited for 2 and 4 hours after the administration of 1.0 mg/kg aprosulate or Calciparin&copy; (7, 500 IU) . Fibrinogen, von Willebrand factor, and RCOF remained in the normal range. There were no significant changes during the study. These results are summarized in Table 1 .
Tolerance
Eleven volunteers complained of burning sensations at the injection site after application of aprosulate. No comments were registered from the subjects receiving heparin. Small local reactions (erythema) were observed in two cases after aprosulate administration, and resolved within 24 hours. . Activated partial thromboplastin time is significantly increased up to 8 hours after 1.0 mg/kg aprosulate and up to 4 hours after 0.5 mg/kg aprosulate. The slight increase with Calciparin&copy; is not significant. Heptest is significantly prolonged after both aprosulate doses and also after Calciparin~ for up to 4 hours. The prolongation of PITT shows a large variation and is most pronounced after 1 mg/kg aprosulate. The differences are not significant. aPTT, activated partial thromboplastin time; PITT, platelet-induced thrombin generation time;
UFH, unfractionated heparin.
Three of 18 subjects had elevated alanine aminotransferase (ALT) levels after each injection, 1 of 18 subjects had elevated aspartate aminotransferase (AST) levels after Calciparin~ and aprosulate of 1.0 mg/kg, respectively, whereas in one volunteer elevated alkaline phophatase values after aprosulate 1.0 mg/kg were registered. Gamma-GT increases were not observed. All TABLE 1. Influence of subcutaneous doses of UFH (7,500 IU) and aprosulate (1:0.5 mglkg; 11:1.0 mglkg) on blood coagulation and platelet adhesion UFH, unfractionated heparin. abnormal laboratory parameters returned to normal within 4 weeks after study completion. There was no decrease in platelet count in any volunteer after any drug/ dose applied.
DISCUSSION
Aprosulate is a new fully synthesized highly sulfated polyanion with anticoagulant and antithrombotic properties. Aprosulate was applied subcutaneously with doses of 0.5 and I mg/kg in this phase I clinical trial in healthy volunteers. Aprosulate significantly and dose dependently prolonged aPTT and Heptest. The effect on aPTT was stronger than the effect of a single subcutaneous dose of 7,500 IU UFH. The aPTT prolongation with the higher aprosulate dose lasted for >8 hours. Baseline values were reached after 12 hours. Heptest was similarly affected but here the effect of UFH was slightly stronger than that of both aprosulate doses. Platelet induced thrombin generation time, which was one of the main target parameters in this study, was slightly but not significantly prolonged by both doses of aprosulate while there was almost no effect of UFH on this test that measures thrombin generation in the presence of platelets. The platelet adhesion index was minimally reduced for 4 hours after I mg/kg aprosulate. Aprosulate and UFH had no effect on fibrinogen, von Willebrand factor, and RCOF.
The results concerning aPTT and Heptest are in agreement with published data (19) . The anticoagulant effect of aprosulate may be contributed to the inhibition of heparin-cofactor II, since aprosulate does not interfere with factor IIa and factor Xa (4, 6, 7, 29) . The more pronounced dose-dependent effect of UFH on Heptest might be due to an increased endothelial tissue factor pathway inhibitor (TFPI) mobilization (30) . The prolongation of Heptest may also be interpreted by a heparin-cofactor mediated mechanism. In contrast to heparin AT III is not needed for the anticoagulant effect of aprosulate (7) , whereas heparin-cofactor II is necessary (31, 32) . In vitro studies suggest that platelet factor 4 does not influence the anticoagulant effect of aprosulate (5) whereas platelet factor 4 binds to heparin neutralizing its anticoagulant activity.
-Aprosulate inhibits thrombin generation in the presence of platelets as shown by the prolongation of PITT in this study. There was a relatively large variation of results. Therefore, the prolongation of PITT is not significant. While UFH affects PITT only at higher concentrations, prophylactic doses of LMWH significantly prolong PITT (24) . So far the effects of LMWH and aprosulate on the PITT system are to some extent comparable and it can be expected that higher doses of aprosulate or the doses used in this study in a large population would lead to a significant prolongation of PITT.
Aprosulate-inhibited thrombin time in a primate model (33) . In animal models of thrombosis no anti-IIaactivities and only small anti-Xa-activities were found implicating that the antiprotease actions of sulfated bislactobionic acid amides are not a prerequisite for their antithrombotic activity (5) . Combinations of aprosulate with LMWHs as shown in a rat thrombosis model had significant additive inhibitory effects on thrombus formation (17) .
Previous reports have also demonstrated that the degree of sulfation is important for the effects of sulfated polysaccharides on thrombin inhibition (11) .
In this study there was no decrease of fibrinogen in contrast with other findings reflecting a mild fibrinolytic effect (18, 31) correlated with an increase of tissue plasminogen activator (TPA) antigen levels (31) . - The observed slight effects on platelet adhesion may be due to an increased release of endogenous mediators leading to an elevation of 6-keto PGFI&OElig; (34) . Interaction with the endothelium by stimulation of heparan sulfate may contribute to the antithrombotic action of aprosulate (13) .
For prevention of thromboembolic complications in clinical studies, aprosulate may have to be given twice daily according to the data obtained in this study. Probably neither Heptest nor aPTT nor any other coagulation assay is suited to predict the antithrombotic efficacy of this agent. The PITT system is not sensitive enough to monitor subcutaneous doses of aprosulate (1.0 mg/kg) or prophylactical doses of UFH (e.g. 7,500 IU Calciparin §).
For antagonization of aprosulate, higher doses of protamine than used for UFH may be necessary in vitro and in vivo (12, 16, 33) .
The effects of aprosulate on liver enzyme suggest that this drug may have similar effects as UFH (35) (36) (37) (38) (39) . If observed more frequently, these changes may become a limiting factor in the development of aprosulate.
CONCLUSIONS
Aprosulate is a new antithrombotic agent that in part has similar effects as those described with LMWH. It is the first representative of a new class of synthetic poly-anions that has shown antithrombotic efficacy in different animal models.
Further clinical studies are necessary to define antithrombotic doses of this new agent in patients at risk for venous or arterial thrombosis.
